Example: Heart Attack
Search clinical trials for: Risedronic acid
Total 0 results
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Medical Conditions
- COVID-19
- Acid Ceramidase Deficiency
- Antifibrinolytic Agents
- Chronic Low Back and Leg Pain
- Diabetic Peripheral Neuropathic Pain
- Drain Insertion Site
- Exhaustion - Physiological
- Hypoxemia and/or Hypercapnia
- Kidney Failure Chronic
- Non-emergent Care
- Pain, Post Surgical
- Post Operative Wound Infection
- Primary Testicular Lymphoma
- Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
- View Full List
Sponsors and Collaborators
- Antios Therapeutics, Inc
- Asturias Public Health Service (SESPA)
- Atrium Medical Center
- Benito Menni
- Centro de Estudos em Sonolência e Acidentes
- Jeil Pharmaceutical Company
- Kind LLC
- Kristen Spencer
- Second Affiliated Hospital of Fujian Traditional Chinese Medical University
- Southampton Clinical Trials Unit
- Taipei Medical University WanFang Hospital
- Tereos
- Uniwersytecki Szpital Kliniczny w Opolu
- View Full List
Drug Interventions
- Arm C DA V FLAG-Ida V DAC
- BPM31510 Oral Nanosuspension 4%
- Cytosar
- Dexamethasone intravitreal implant
- Fluticasone propionate/ salmeterol combination 50/500mcg
- Galantamine 4 mg Tablet, single dose
- Ifosfamide, carboplatin, and etoposide (ICE) regimen
- Nivolumab + Ipilimumab
- Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Satoreotide trizoxetan 5-20μg
- Transplant 2 Etoposide
- nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- sodium hyaluronate 0.18% (VISMED® Multi)
- View Full List
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations